Regenxbio Inc（RGNX）の株式分析RGNXRegenxbio Inc

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Regenxbio Inc (RGNX) is currently not a strong buy due to its low current price of $6.68 and a concerning RSI of 30.239, indicating oversold conditions. While there are positive catalysts such as the potential FDA accelerated approval for RGX-202 and a projected upside of 196% from analysts, the company has faced significant challenges, including a 50.77% year-to-date decline and increased insider selling by 218.11%. The main risk is the ongoing clinical hold on RGX-121, which could delay future growth prospects.

5 analysts cover RGNX: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 29.71.